Search
for
Sort by
Research 931–960 of 1000+
- Uncovering novel biomarkers and drug targets for androgenetic alopecia via metabolite regulation and multi-tissue validation
- Composite Hydrogel Dressing with Drug-Release Capability and Enhanced Mechanical Performance
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch
- 5-Fluorouracil induces hair loss by inhibiting β-catenin signaling and angiogenesis
- In vitro 5α-reductase inhibition by selected Ayurvedic herbs for androgenic disorders
- ANDROGENINĖS ALOPECIJOS MEDIKAMENTINIO GYDYMO GALIMYBĖS
- Adverse effects of the 5-alpha-reductase inhibitor finasteride on Daphnia magna: Endocrine system and lipid metabolism disruption
- Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
- The role of fractional laser‐assisted drug delivery in enhancing the efficacy of topical bimatoprost solution in the treatment of alopecia areata: An intra‐patient comparative randomized clinical trial
- Analysis of Adverse Drug Reactions in Pediatric Patients with Epilepsy: An Intensive Pharmacovigilance Study
- Study of Drug Target Identification and Associated Molecular Mechanisms for the Therapeutic Activity and Hair Follicle Induction of Two Ashwagandha Extracts Having Differential Withanolide Constitutions
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- A systematic review on Drug Re-profiling/Re-Purposing
- Faculty Opinions recommendation of Association between 5-alpha reductase inhibition and risk of hip fracture.
- Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease
- Review of Drug Repositioning in Cancer Therapeutics
- Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis
- Finasteride: the first 5 alpha-reductase inhibitor.
- Formulation of Sodium Valproate Nanospanlastics as a Promising Approach for Drug Repurposing in the Treatment of Androgenic Alopecia
- Tales of bugs, delusions of parasitosis, and what to do
- 5‐Alpha reductase inhibitor related litigation: A legal database review
- Screening of dermatology drugs for aberrant use‐patterns: An application of epidemiologic estimates and measures of inequality in drug use
- Application of the waiting time distribution in a nationwide screening of real‐world dermatology drug utilization for aberrant use patterns
- Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
- Evaluation of an eucalyptus oil containing topical drug delivery system for selected steroid hormones
- Comparison of Finasteride (Proscar®) and Serenoa repens (Permixon®) in the Inhibition of 5-Alpha Reductase in Healthy Male Volunteers
- Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work
- PROTACs: A novel strategy for cancer drug discovery and development
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata